Khiron Life Sciences Corp. (OTCMKTS:KHRNF) has pulled through in its mission to expand its Cultivation Jurisdiction. Having entered into an MOU with Dayacann, the integrated medical cannabis company will easily access the Chilean market. Dayacann is the holder of Chile’s first medical cannabis cultivation license and has been in cultivation for two years. Khiron will ride on the fact that Dayacann has dominated Latin America, a status, which will accelerate its Khiron’s objective.
Chile has a population of 18 million people. It has the most robust economy in Latin America. It is considered a prosperous nation with a stable economy and an established cannabis culture. It was the first to embrace the approval of cultivation of cannabis for medicinal purposes in Latin America.
New and lower-cost alternative medicines will help diversify options for Chilean patients
Chile presents a medical cannabis market of 1.8 million potential patients. A majority of patients cannot access the traditional prescription for various conditions such as epilepsy, depression, and anxiety. Thus, cannabis comes in handy as a low-cost alternative to Chilean patients. Records have it that there are usually more than 45.000 patients annually.
The CEO of Khiron life Sciences, Alvaro Torres, notes, “As part of our multi-jurisdiction cultivation strategy… partnering with Dayacann allows us to accelerate entry into this market and to further our stated objective to be the medical cannabis market leader in Latin America.” The partnership will also create quality jobs according to the CEO of Dayacann Spa, Nicolás Dormal.
Khiron Life Sciences focus on regional strategy and patient-oriented approach
The company has its core functions in Colombia. It has the license for cultivation, production, and distribution of THC and CBD locally and internationally. It capitalizes on patient-oriented approach in meeting their needs. Khiron combines experience, expertise, and loyalty in serving its global customers.
The company has established a partnership with Farmalisto, which will accelerate the distribution of its wellness brand Kuida. It is taking advantage of Mexico’s rapid move to legalize cannabis and also the fact that the Mexican market is significantly more significant compared to its Canadian counterpart. However, the former has no competition, and this is good news for Khiron.